Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit

Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit

Background: Intraperitoneal chemotherapy using paclitaxel (i.p.-PTX) is expected to be a new therapeutic strategy for patients with pancreatic ductal adenocarcinoma (PDAC) and peritoneal dissemination. We evaluated the survival benefit of i.p.-PTX compared with standard systemic chemotherapy. Method...

Full description

Bibliographic Details
Main Authors: Tomohisa Yamamoto, Sohei Satoi, So Yamaki, Daisuke Hashimoto, Mitsuaki Ishida, Tsukasa Ikeura, Satoshi Hirooka, Yuki Matsui, Shogen Boku, Shinji Nakayama, Koh Nakamaru, Nobuhiro Shibata, Utae Katsushima, Mitsugu Sekimoto
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
pancreatic cancer
peritoneal dissemination
intraperitoneal therapy
paclitaxel
Online Access:https://www.mdpi.com/2072-6694/14/5/1354

Internet

https://www.mdpi.com/2072-6694/14/5/1354

Similar Items